FDA Approves Generic Versions of Lilly's Antidepressant Cymbalta

Source: FDA

Dec 12, 2013

The FDA has granted approval for the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription antidepressant that is currently Eli Lilly's top-selling drug.

Cymbalta's patent expired Wednesday, opening doors for six generic drugmakers. Teva Pharmaceuticals USA as well as India's Aurobindo Pharma, Dr. Reddy’s Laboratories, Lupin, Sun Pharma Global and Torrent Pharmaceuticals have received FDA approval to market duloxetine in various strengths.

According to AP News, Lilly's Cymbalta posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world.

Read the FDA press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments